Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04211480

Recruitment Status : Completed

First Posted : December 26, 2019

Last Update Posted : January 5, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Xiangya Hospital of Central South University

The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

Information provided by (Responsible Party):

Bioray Laboratories

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	October 15, 2023
Actual Study Completion Date :	November 27, 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Fu B, Liao J, Chen S, Li W, Wang Q, Hu J, Yang F, Hsiao S, Jiang Y, Wang L, Chen F, Zhang Y, Wang X, Li D, Liu M, Wu Y. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric beta0/beta0 transfusion-dependent beta-thalassemia. Nat Med. 2022 Aug;28(8):1573-1580. doi: 10.1038/s41591-022-01906-z. Epub 2022 Aug 4.

Brusson M, Miccio A. Genome editing approaches to beta-hemoglobinopathies. Prog Mol Biol Transl Sci. 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1.

To Top